GlobeNewswire
-
Survey reveals care navigation gap when patients must decide when and where to get help
18/11/2026 -
Finish Strong, Start Strong: Austin Sports Medicine Experts Urge Athletes and Families to Prioritize Injury Recovery Before the New Year
18/11/2026 -
BC launches first-of-its-kind jointly held professorship in menopause research and education
18/11/2026 -
Texas Original’s Fort Worth Medical Cannabis Dispensary Now Offers Same-Day Access
18/11/2026 -
Virbac to Participate in the Jefferies Global Healthcare Conference in London
18/11/2026 -
Can-Fite Pivotal Phase III Psoriasis Study Under an FDA- and EMA-agreed protocol: All Patients Completed Dosing and Interim Analysis Expected Q1 2027
18/11/2026 -
Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD
18/11/2026 -
Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
18/11/2026 -
Nyxoah Obtient une Décision par Défaut contre Inspire Medical Systems dans une Procédure devant l’Unified Patent Court
18/11/2026 -
Nyxoah Obtains Default Decision Against Inspire Medical Systems in Unified Patent Court Case
18/11/2026 -
Olema Oncology Presents Preclinical Data on Selective KAT6A Degraders in ER+/HER2- Breast Cancer Models at EORTC-NCI-AACR Symposium
18/11/2026 -
Adaptive Biotechnologies Highlights clonoSEQ’s Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026
18/11/2026 -
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
18/11/2026 -
UREVO Announces Black Friday Sale 2026 with Its Biggest Discounts of the Year
18/11/2026 -
Medline Inc. announces pricing of secondary offering of Class A common stock
18/11/2026 -
Novartis showcases hematology momentum and continued breast cancer leadership at ASH and SABCS
18/11/2026 -
Novo Nordisk Foundation commits US$60 million to strengthen CARB-X efforts against antimicrobial resistance
18/11/2026 -
Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight
18/11/2026 -
CytomX Therapeutics Announces Milestone Achievement in Strategic Collaboration with Regeneron in the Field of Conditionally Activated Bispecifics
17/11/2026
Pages